| 赵振杰,李志刚,徐科,等.抗血管内皮生长因子联合地塞米松玻璃体内植入剂在黄斑水肿中的临床应用[J].安徽医药,2025,29(4):637-641. |
| 抗血管内皮生长因子联合地塞米松玻璃体内植入剂在黄斑水肿中的临床应用 |
| Clinical application of anti-vascular endothelial growth factor drugs combined with dexamethasone intravitreal implants in macular edema |
| |
| DOI：10.3969/j.issn.1009-6469.2025.04.001 |
| 中文关键词: 黄斑水肿 血管内皮生长因子 抗血管内皮生长因子药物 地塞米松 玻璃体 植入剂 治疗效果 |
| 英文关键词: Macular edema Vascular endothelial growth factor Anti-vascular endothelial growth factor drugs Dexamethasone Vitreous body Implant Therapeutic effect |
| 基金项目:三门峡市科技发展计划项目( 2022002043) |
|
| 摘要点击次数: 488 |
| 全文下载次数: 230 |
| 中文摘要: |
| 近年来，抗血管内皮生长因子( VEGF)、类固醇皮质激素逐渐被广泛应用于黄斑水肿的治疗。然而，这些药物的作用期限相对有限，因此需要定期进行注射以维持治疗效果。地塞米松玻璃体内植入剂是一种缓释药物制剂，通常用于治疗与视网膜相关的疾病，一般药效可维持 6个月左右。考虑到黄斑水肿发病中 VEGF升高、炎症作用同时存在，已有部分学者研究抗 VEGF药物联合地塞米松玻璃体内植入剂的治疗方案。该研究就抗 VEGF药物联合地塞米松玻璃体内植入剂在黄斑水肿中的临床应用进展进行综述。 |
| 英文摘要: |
| In recent years, anti-vascular endothelial growth factor (VEGF) agents and corticosteroids have been gradually and widelyapplied in the treatment of macular edema. However, the duration of action of these medications is relatively limited, requiring regularinjections to maintain therapeutic effects. Dexamethasone intravitreal implants are a sustained-release drug formulation commonly used to treat retinal-related diseases, with their effect generally lasting around six months. Considering the simultaneous presence of elevatedVEGF and inflammatory processes in the pathogenesis of macular edema, some researchers have studied the combination of anti-VEGF drugs and dexamethasone intravitreal implants as a treatment strategy. This article reviews the clinical application progress of combin.ing anti-VEGF drugs and dexamethasone intravitreal implants in macular edema. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
